Pharmaceuticals

Efcitra demonstrates non-inferiority to insulin glargine and degludec in type 2 diabetes

bexib
By bexib 0 Min Read

Results from the QWINT-1 and QWINT-3 trials showed that insulin-naive patients experienced similar reductions in A1C levels with once-weekly Efcitra compared with daily insulin glargine and degludec.

You Might Also Like

FDA Grants Orphan Drug Designation to MabWell’s Small Cell Lung Cancer Treatment

Beyond Fertility: The Social Cost of Maternal Mortality

Pharmaceutical Executive: July/August 2024 issue (PDF)

FDA approves Voquezna for GERD treatment

US researchers develop AI liquid biopsy test to help detect lung cancer early

Share This Article
Previous Article Optimized landing pages reduce advertising costs
Next Article Calculated risk and reward! July existing home sales increase to 3.95 million SAAR
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Automobile companies battle AI bots and recruitment competition
Banking
IMTEX, Tooltech & Digital Manufacturing 2025
Manufacturing
“Your money or your life” is defined by Google
Retail & E-commerce
Easy-to-understand English guide to Shopify Liquid
Retail & E-commerce